Form 4: DBV Technologies CMO Sells Shares for Tax Obligations

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 534 ordinary shares for $4.86 each to cover tax obligations related to restricted stock unit vesting.

Summary

• Pharis Mohideen, Chief Medical Officer of DBV Technologies S.A. (DBVT), reported a transaction involving the sale of ordinary shares.
• On January 29, 2026, Mohideen disposed of 534 ordinary shares at a price of $4.86 per share.
• The sale was conducted to satisfy withholding tax obligations arising from the vesting of restricted stock units.
• Following this transaction, Mohideen beneficially owns 144,995 ordinary shares.
• Ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is non-discretionary, solely for tax purposes, and does not indicate a change in the executive's confidence or the company's fundamentals.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations upon the vesting of restricted stock units are a common and routine occurrence across all industries. Such transactions are typically non-discretionary and do not necessarily reflect management's sentiment about the company's future prospects.

Comparison to Industry Standards

• This type of transaction (sale to cover tax obligations) is standard practice for executives receiving equity compensation across publicly traded companies globally, including peers in the biotechnology and pharmaceutical sectors such as Sanofi, Novartis, and Pfizer. The volume of shares sold is relatively small compared to the executive's total holdings, which is typical for tax-related sales.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small volume and non-discretionary nature of the sale. It does not signal a change in company fundamentals or executive confidence.
• Employees: No direct impact indicated by this filing.
• Customers: No direct impact indicated by this filing.
• Suppliers: No direct impact indicated by this filing.
• Creditors: No direct impact indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of a small number of shares by an executive to cover tax obligations. It provides no new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not present a compelling reason to buy or sell based on fundamental analysis.

Keywords

DBV Technologies, DBVT, Form 4, Insider Transaction, Share Sale, Chief Medical Officer, Restricted Stock Units, Tax Obligations